VivoSim Labs, INC.

CIK 1497253 VIVS·Biological Products · All EDGAR filings ↗

Progression

2026-07-14 Going concern 10-K
2026-11-12 Revenue recognition change 10-Q +121d

Refine

An amendment is grouped with the report it amends; every 12b-25 notice is one group

Revenue recognition change beta Filing comparison 2026-11-12

VivoSim Labs, INC. changed its revenue recognition disclosure

Revenue is recognized when the underlying sales occur and the related performance obligation has been satisfied.

Evidence

New language: Revenue is recognized when the underlying sales occur and the related performance obligation has been satisfied., Service revenue, net The Company markets and offers liver and intestinal toxicology and disease (or efficacy, used interchangeably) predictive screening research services using new approach methodologies (“NAM”) to pharmaceutical and biotech companies at all stages of drug development.
Prior filed: 2026-08-12
Prior form: 10-Q
Similarity: 0.55
Source: revenue recognition note comparison
Threshold: 0.6
Why: The revenue recognition policy disclosure changed materially from the previous comparable filing.

Language present now, absent from the prior filing:

Revenue is recognized when the underlying sales occur and the related performance obligation has been satisfied.
Service revenue, net The Company markets and offers liver and intestinal toxicology and disease (or efficacy, used interchangeably) predictive screening research services using new approach methodologies (“NAM”) to pharmaceutical and biotech companies at all stages of drug development.

Source filing ↗ Prior filing ↗

Going concern Filing comparison 2026-07-14

VivoSim Labs, INC. disclosed substantial doubt about its ability to continue as a going concern

No going-concern disclosure → Substantial doubt about ability to continue as a going concern

Going Concern Uncertainty The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has incurred recurring losses and negative cash flows from operations and is dependent on additional financing to fund operations. These conditions raise substantial doubt about its ability to continue as a going concern. Management’s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments…

Evidence

Blank check: No
Comparable: Yes
Current state: substantial_doubt
Current state label: Substantial doubt about ability to continue as a going concern
Direction: escalated
Located in: going-concern note
Prior filed: 2025-07-29
Prior form: 10-K/A
Prior state: none
Prior state label: No going-concern disclosure
Source: ASC 205-40 going-concern note comparison
Why: Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Late filing elevated Filing comparison 2026-06-29

VivoSim Labs, INC. told the SEC it could not file its annual report on time

Does not expect a significant change in results. Filed on the statutory due date.

(the “Registrant”) has determined that it is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended March 31, 2026 (the “Form 10-K”) by June 29, 2026, the prescribed due date, because it requires more time to gather necessary information for the preparation and finalization of its financial statements and other disclosures to be included in the Form 10-K. The Registrant is working diligently to complete the Form 10-K as soon as practicable, which the Registrant anticipates will not be later than the fifteenth calendar day following the prescribed due date for the Form 10-K, or July 14, 2026.

Evidence

Anticipates significant change: No
Days past due date: 0
Other periodic reports filed: Yes
Routine: No
Severity: elevated
Source: Form 12b-25 (notification of late filing)
Stated reason: (the “Registrant”) has determined that it is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended March 31, 2026 (the “Form 10-K”) by June 29, 2026, the prescribed due date, because it requires more time to gather necessary information for the preparation and finalization of its financial statements and other disclosures to be included in the Form 10-K. The Registrant is working diligently to complete the Form 10-K as soon as practicable, which the Registrant anticipates will not be later than the fifteenth calendar day following the prescribed due date for the Form 10-K, or July 14, 2026.
Why: The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗